Xoma Has Acquired An Economic Interest In Three Women's Health Assets From Daré Bioscience For An Upfront Payment Of $22M
Portfolio Pulse from Benzinga Newsdesk
Xoma has acquired an economic interest in three women's health assets from Daré Bioscience for an upfront payment of $22M, including interests in Ovaprene and Sildenafil Cream. Organon has initiated XACIATO commercial activities, and Bayer HealthCare holds exclusive rights to Ovaprene in the U.S.

April 30, 2024 | 11:36 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Daré Bioscience receives a $22M upfront payment from Xoma, which could provide financial flexibility and support for its projects.
The $22M upfront payment from Xoma to Daré Bioscience for the economic interests in women's health assets provides Daré with significant non-dilutive capital. This influx of funds could support ongoing projects and operations, potentially leading to positive investor sentiment.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 90
POSITIVE IMPACT
Xoma's acquisition of economic interests in women's health assets from Daré Bioscience for $22M could enhance its portfolio and investor appeal.
The acquisition of economic interests in three women's health assets, including late-stage candidates, significantly enhances Xoma's portfolio, potentially increasing its market value and investor interest due to the expansion into women's health.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90